Related Experiment Video

Updated: May 18, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

IFN-α in the treatment of melanoma

Ahmad A Tarhini1, Helen Gogas, John M Kirkwood

  • 1Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA. tarhiniaa@upmc.edu

Journal of Immunology (Baltimore, Md. : 1950)
|October 9, 2012
PubMed

Insights

High-dose interferon-alfa-2b (IFN-α2b) is the only regimen showing durable survival benefits as adjuvant therapy for high-risk melanoma. Pegylated IFN-α2b also demonstrated relapse-free survival advantages in specific patient groups.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Interferon-alfa (IFN-α) exhibits diverse anti-cancer effects including antiangiogenic, immunoregulatory, differentiation-inducing, antiproliferative, and proapoptotic activities.
  • IFN-α2 is the most clinically studied subtype of IFN-α, with various dosing regimens explored in melanoma treatment.

Purpose of the Study:

  • To evaluate the efficacy of different interferon-alfa-2b (IFN-α2b) regimens as adjuvant therapy for high-risk melanoma.
  • To determine the impact of adjuvant IFN-α2b on relapse-free and overall survival in melanoma patients.

Main Methods:

  • Analysis of data from Eastern Cooperative Oncology Group and intergroup trials (E1684, E1690, E1694) evaluating high-dose IFN-α2b in surgically resected, high-risk melanoma (stage IIB or III).
  • Evaluation of adjuvant pegylated IFN-α2b in the European Organization for Research and Treatment of Cancer trial 18991, comparing maximally tolerable doses against observation in patients with microscopic nodal disease.

Main Results:

  • High-dose IFN-α2b demonstrated a durable impact on both relapse-free and overall survival in patients with stage IIB or III melanoma.
  • Adjuvant pegylated IFN-α2b showed relapse-free survival benefits for patients with microscopic nodal disease.

Conclusions:

  • High-dose IFN-α2b is a validated adjuvant therapy for high-risk melanoma, offering significant survival improvements.
  • Pegylated IFN-α2b provides a survival benefit in specific melanoma patient subgroups, warranting its consideration in adjuvant settings.

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth06:35

A Mouse Model to Investigate the Role of Cancer-Associated Fibroblasts in Tumor Growth

Published on: December 22, 2020

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...